Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11158880 | 0.84 | PTPN1 (0.51) | PTPN1GSK3BPDPK1CES2CES1 | |
| SCHEMBL194868 | 0.81 | SMN1; SMN2 (0.50) | PTPN1CES2CES1HSD11B1ALDH1A1 | |
| SCHEMBL3408059 | 0.79 | PTPN1 (0.46) | PTPN1GSK3BPDPK1CES2CES1 | |
| SCHEMBL28221563 | 0.79 | GSK3B (0.53) | GSK3BCES2CES1HDAC1HDAC8 | |
| SCHEMBL19642328 | 0.77 | PDPK1 (0.65) | PTPN1GSK3BPDPK1CES2CES1 | |
| SCHEMBL18860300 | 0.77 | PTPN1 (0.59) | PTPN1GSK3BPDPK1CES2CES1 | |
| SCHEMBL133449 | 0.77 | PTPN1 (0.59) | PTPN1GSK3BPDPK1CES2CES1 | |
| SCHEMBL193893 | 0.77 | ALDH1A1 (0.50) | GSK3BCES2CES1HDAC1HDAC8 | |
| SCHEMBL194701 | 0.77 | GSK3B (0.52) | GSK3BPDPK1CES2CES1ALDH1A1 | |
| SCHEMBL194154 | 0.77 | TSHR (0.57) | PTPN1GSK3BCES1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | PTPN1 549/4885GSK3B 4622/4885PDPK1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.